SC
AZN icon

Schubert & Co’s AstraZeneca AZN Stock Holding History

Schubert & Co’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-124
Closed -$17.1K – 169
2023
Q1 		$17.1K Buy
124
+6
+5% +$807 0.02% 148
2022
Q4 		$16K Buy
118
+11
+10% +$1.38K 0.01% 136
2022
Q3 		$12K Buy
107
+23
+27% +$2.92K 0.01% 163
2022
Q2 		$11K Buy
+84
New +$11K 0.01% 167

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Schubert & Co's AZN Position: Q2 2023 in Review

Schubert & Co sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 124 shares — an estimated $17.1K sold.

Schubert & Co first reported a position in AZN in Q2 2022 and held it in 4 quarters. The position peaked at $17.1K in Q1 2023. 1,090 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

  • Schubert & Co reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 124 AstraZeneca shares in Q2 2023, an estimated $17.1K.
  • Schubert & Co first reported a position in AstraZeneca in Q2 2022 and held it in 4 quarters.
  • Schubert & Co's AstraZeneca position peaked at $17.1K in Q1 2023.
  • 1,090 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.